Drug Profile
Research programme: GlcNAc-TV inhibitors - Inflazyme
Alternative Names: GlcNAc-TV inhibitors research programme - InflazymeLatest Information Update: 30 Jul 2004
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2004 No development reported - Preclinical for Cancer in Canada (PO)
- 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals
- 16 Aug 2002 This programme is still in active development